DBV Technologies | DBVT - Ebitda


DBV Technologies reported $-45.9M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD -1.62M 21.94M Mar/2026
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
Amarin USD 12.54M 28.57M Jun/2025
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
DBV Technologies USD -45.9M 12.42M Mar/2026
Galectin Therapeutics USD -7.42M 819K Dec/2021
Halozyme Therapeutics USD 219.57M 197.66M Mar/2026
Incyte USD 778.57M 410.6M Jun/2026
Insmed USD -148.3M 165.88M Mar/2026
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
PTC Therapeutics USD 61.98M 132.97M Mar/2026
Sarepta Therapeutics USD 375.48M 627.68M Mar/2026
Ultragenyx Pharmaceutical USD -155M 55.57M Mar/2026
United Therapeutics USD 355M 11.1M Jun/2026